The compound sensitized bladder cancer cells to the proteasome inhibitor bortezomib (Velcade®) in a similar manner to the action of a sh-RNA-mediated silencing of the major stress-inducible member HSP70 (HSPA1A) [53]. The gene discussed is HSPA1A; the disease is urinary bladder cancer.